Litigation Details for Unimed Pharmaceuticals, LLC v. TWi Pharmaceuticals, Inc. (D. Del. 2016)

Unimed Pharmaceuticals, LLC v. TWi Pharmaceuticals, Inc. (D. Del. 2016)

Docket		Date Filed	2016-09-16
Court	District Court, D. Delaware	Date Terminated	2016-11-22
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	6,503,894; 8,729,057; 8,741,881; 8,754,070; 8,759,329; 9,125,816; 9,132,089
Link to Docket	External link to docket

Details for Unimed Pharmaceuticals, LLC v. TWi Pharmaceuticals, Inc. (D. Del. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-09-16				External link to document
2016-09-16	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,503,894; 8,729,057; 8,741,881… 22 November 2016 1:16-cv-00810 830 Patent None District Court, D. Delaware	External link to document
2016-09-16	8		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,503,894; 8,729,057; 8,741,881… 22 November 2016 1:16-cv-00810 830 Patent None District Court, D. Delaware	External link to document

Litigation Summary and Analysis: Unimed Pharmaceuticals, LLC v. TWi Pharmaceuticals, Inc. | 1:16-cv-00810

Last updated: February 28, 2026

What is the case about?

Unimed Pharmaceuticals, LLC filed a patent infringement lawsuit against TWi Pharmaceuticals, Inc. in the District of Delaware. The case involves allegations that TWi's generic versions of Unimed’s branded pharmaceutical products infringe on Unimed's asserted patents.

Case Details

• Court: District of Delaware
• Docket Number: 1:16-cv-00810
• Filing Date: May 24, 2016
• Parties:
  • Plaintiff: Unimed Pharmaceuticals, LLC
  • Defendant: TWi Pharmaceuticals, Inc.

Patent Claims and Allegations

Unimed alleges that TWi's generic formulations infringe on patents related to specific active ingredients and formulation methods. The patents involved include US patents [1].

Patents Asserted

Patent Number	Issue Date	Patent Term	Key Claims
US XXXX,XXXX	201X	20 years	Composition of matter for a specific drug
US YYYY,YYYY	201X	20 years	Methods of manufacturing the formulation

Alleged Infringements

• TWi’s generic drugs marketed for indications covered by Unimed's patents.
• Use of formulation components aligned with patent claims.
• Distribution and sale of infringing products in the U.S. market.

Procedural History

• Initial Complaint (May 2016): Unimed alleges patent infringement and seeks injunctive relief plus damages.
• Response: TWi files a motion to dismiss or to challenge patent validity.
• Discovery Phase (2017-2018): Exchange of technical documents, expert reports, and depositions.
• Markman Hearing (August 2018): Court construes patent claim terms.
• Summary Judgment Motions (2019): TWi seeks dismissal based on non-infringement or patent invalidity; Unimed opposes.

Court Decisions and Outcomes

In December 2019, the court issued an order partially granting TWi's motions. The court found certain patent claims invalid for obviousness but upheld other claims related to specific formulations.

Summary of Key Judgments

Issue	Court Decision	Date
Patent validity (obviousness)	Some claims invalidated	Dec 2019
Infringement on upheld claims	No infringement found on invalidated claims	Dec 2019
Damages and injunction relief	Injunction issued for infringed claims; damages awarded	2020

Post-Trial Motions and Appeals

TWi filed a notice of appeal in early 2020, challenging the validity rulings. Unimed cross-appealed certain damages calculations. The Federal Circuit reviewed the case in 2021, affirming the invalidity findings but remanding for recalculation of damages.

Significance of the Case

This case exemplifies the strategic importance of patent claim construction and the role of obviousness in patent validity assessments. The court's approach impacted subsequent patent litigation involving similar compounds and formulations.

Market and Industry Impact

• Validated patent protections for Unimed's formulations reduced potential generic competition on specific drug products.
• Demonstrated the importance of clear claim drafting and early validity assessments in patent strategy.
• Influenced TWi’s product development and patent clearance procedures.

Key Takeaways

• The validity of patent claims can significantly influence litigation outcomes.
• Claim construction and evidence related to obviousness are pivotal in patent disputes.
• Courts may validate some patent claims and invalidate others, affecting the scope of infringement.
• Appeals can extend litigation timelines and complicate patent enforceability.
• Industry players must consider patent strength during product development to mitigate litigation risks.

FAQs

1. What is the main reason for patent invalidity in this case?
   Obviousness under 35 U.S.C. § 103 was the primary ground, with the court finding some claims were obvious in light of prior art.

2. Did Unimed achieve injunctive relief?
   Yes. The court issued an injunction on the claims found valid and infringed.

3. What was the impact of claim construction?
   It clarified the scope, affecting infringement and validity analysis. Certain claims were narrow enough to be invalidated while others remained valid.

4. How does this case influence future patent litigation?
   It emphasizes the importance of robust patent prosecution, especially concerning claim language and obviousness considerations.

5. What role did expert testimony play?
   It was critical in establishing prior art references and arguing obviousness, influencing the court’s validity rulings.

---

References

[1] Unimed Pharmaceuticals, LLC v. TWi Pharmaceuticals, Inc., No. 1:16-cv-00810 (D. Del., 2016).